Merck & Co., Inc. (NYSE:MRK) Expected to Post Quarterly Sales of $13.72 Billion

Equities research analysts expect that Merck & Co., Inc. (NYSE:MRKGet Rating) will announce $13.72 billion in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Merck & Co., Inc.’s earnings, with the highest sales estimate coming in at $14.57 billion and the lowest estimate coming in at $13.13 billion. Merck & Co., Inc. posted sales of $11.40 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 20.4%. The company is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Merck & Co., Inc. will report full-year sales of $57.02 billion for the current year, with estimates ranging from $56.88 billion to $57.20 billion. For the next year, analysts anticipate that the business will post sales of $55.05 billion, with estimates ranging from $54.46 billion to $55.63 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its earnings results on Thursday, April 28th. The company reported $2.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.31. Merck & Co., Inc. had a net margin of 26.02% and a return on equity of 47.24%. The business had revenue of $15.90 billion during the quarter, compared to the consensus estimate of $14.64 billion. During the same quarter last year, the firm earned $1.40 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 31.6% on a year-over-year basis.

A number of brokerages have recently issued reports on MRK. Morgan Stanley reduced their price objective on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. JPMorgan Chase & Co. cut their price target on shares of Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating on the stock in a report on Friday, January 28th. SVB Leerink lowered their price target on shares of Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. StockNews.com began coverage on shares of Merck & Co., Inc. in a report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Finally, Barclays boosted their price target on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $90.69.

MRK opened at $88.69 on Friday. Merck & Co., Inc. has a 1-year low of $70.89 and a 1-year high of $91.40. The company has a current ratio of 1.27, a quick ratio of 1.02 and a debt-to-equity ratio of 0.80. The company has a market cap of $224.19 billion, a P/E ratio of 17.25, a price-to-earnings-growth ratio of 1.40 and a beta of 0.45. The company has a fifty day moving average price of $81.53 and a two-hundred day moving average price of $80.10.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. OLD Mission Capital LLC bought a new stake in Merck & Co., Inc. in the third quarter worth $247,000. Morgan Stanley boosted its stake in Merck & Co., Inc. by 17.1% during the second quarter. Morgan Stanley now owns 26,289,496 shares of the company’s stock worth $2,044,534,000 after buying an additional 3,832,086 shares during the period. Keudell Morrison Wealth Management boosted its stake in Merck & Co., Inc. by 2.5% during the third quarter. Keudell Morrison Wealth Management now owns 18,332 shares of the company’s stock worth $1,377,000 after buying an additional 453 shares during the period. New World Advisors LLC purchased a new position in Merck & Co., Inc. during the third quarter worth $414,000. Finally, Private Portfolio Partners LLC boosted its stake in Merck & Co., Inc. by 50.3% during the third quarter. Private Portfolio Partners LLC now owns 8,926 shares of the company’s stock worth $670,000 after buying an additional 2,988 shares during the period. Institutional investors own 72.05% of the company’s stock.

Merck & Co., Inc. Company Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Further Reading

Get a free copy of the Zacks research report on Merck & Co., Inc. (MRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.